TMT2005-13R - Phase I Open Label, Single Arm, Dose Escalation Trial to Evaluate the Biodistribution and Safety of AHN-12 [anti-CD45 monoclonal antibody] in Patients With Advanced Leukemia.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Anti-CD45 monoclonal antibody Y-90 (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacodynamics; Pharmacokinetics
- 29 Nov 2017 Biomarkers information updated
- 14 May 2010 Planned end date changed from 1 Jul 2008 to 1 Dec 2007 as reported by ClinicalTrials.gov.
- 14 May 2010 Actual patient number (4) added as reported by ClinicalTrials.gov.